Journal of Clinical Immunology

, Volume 33, Issue 2, pp 335–341 | Cite as

Serotype-Specific Anti-Pneumococcal IgG and Immune Competence: Critical Differences in Interpretation Criteria When Different Methods are Used

  • Anne BallochEmail author
  • Paul V. Licciardi
  • Mimi L. K. Tang
Original Research



Serotype-specific antibody responses to pneumococcal polysaccharide are important in evaluating humoral immune function. Multiplex technologies allow simultaneous quantitation of multiple serotype-specific antibodies however there has been limited validation against the gold-standard ELISA and assay performance in the clinical setting has not been examined.

Methods and Materials

Pre- and post-immunization samples were analysed by both methods. The ability to correctly identify an adequate response to polysaccharide vaccine (as defined by current AAAAI guidelines) was determined.


The xMAP Pneumo 14 multiplex assay correlated poorly with the ELISA, particularly for pre-immunization and infant samples. An adequate response to pneumococcal immunization was ‘correctly’ predicted by xMAP Pneumo for 21 of 26 (81 %) adult pairs and 18 of 25 (72 %) infant pairs. Seven of 25 infants and 4 of 26 adults were identified as having an inadequate response by ELISA and an adequate response by xMAP.


When applying current AAAAI guidelines, the xMAP Pneumo 14 assay does not allow reliable evaluation of antibody responses to polysaccharide antigens for the assessment of humoral immune competence. New guidelines for an adequate response should be established for new technologies when evaluating responses to polysaccharide vaccine in the clinical setting.


Pneumovax prevnar immune response multiplex ELISA 

Supplementary material

10875_2012_9806_MOESM1_ESM.docx (20 kb)
ESM 1 (DOCX 19 kb)


  1. 1.
    WHO. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). 2004.
  2. 2.
    Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 2010;134:198–205.PubMedCrossRefGoogle Scholar
  3. 3.
    Biagini RE, Schlottmann SA, Sammons DL, Smith JP, Snawder JC, Striley CA, et al. Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol. 2003;10:744–50.PubMedGoogle Scholar
  4. 4.
    Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods. 2005;296:135–47.PubMedCrossRefGoogle Scholar
  5. 5.
    Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol. 2002;117:589–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Pickering JW, Larson MT, Martins TB, Copple SS, Hill HR. Elimination of false-positive results in a luminex assay for pneumococcal antibodies. Clin Vaccine Immunol. 2010;17:185–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Coughlin RT, White AC, Anderson CA, Carlone GM, Klein DL, Treanor J. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine. 1998;16:1761–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Tarrago D, Aguilar L, Jansen WT, Gimenez MJ, Avellon A, Granizo JJ, et al. Dependence of correlations between antibody titres and opsonophagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states. Clin Microbiol Infect. 2007;13:369–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Yu X, Sun Y, Frasch C, Concepcion N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol. 1999;6:519–24.PubMedGoogle Scholar
  10. 10.
    Plikaytis BD, Goldblatt D, Frasch CE, Blondeau C, Bybel MJ, Giebink GS, et al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol. 2000;38:2043–50.PubMedGoogle Scholar
  11. 11.
    Whaley MJ, Rose C, Martinez J, Laher G, Sammons DL, Smith JP, et al. Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol. 2010;17:862–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Russell FM, Balloch A, Tang ML, Carapetis JR, Licciardi P, Nelson J, et al. Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2009;27:5685–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Balloch A, Licciardi PV, Leach A, Nurkka A, Tang ML. Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance. Vaccine. 2010;28:1333–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2007;99:462–4.CrossRefGoogle Scholar
  15. 15.
    Elberse KE, Tcherniaeva I, Berbers GA, Schouls LM. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol. 2010;17:674–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Soininen A, Karpala M, Wahlman SL, Lehtonen H, Kayhty H. Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children. Clin Diagn Lab Immunol. 2002;9:1032–8.PubMedGoogle Scholar
  17. 17.
    Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8:266–72.PubMedGoogle Scholar
  18. 18.
    Skovsted IC, Kerrn MB, Sonne-Hansen J, Sauer LE, Nielsen AK, Konradsen HB, et al. Purification and structure characterization of the active component in the pneumococcal 22 F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine. 2007;25:6490–500.PubMedCrossRefGoogle Scholar
  19. 19.
    Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I. Evaluation of pneumococcal polysaccharide immunoassays using a 22 F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol. 2010;17:134–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Bondada S, Wu H, Robertson DA, Chelvarajan RL. Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine. 2000;19:557–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis. 1984;149:861–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis. 1983;148:131–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J. 1999;18:543–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Karma P, Luotonen J, Timonen M, Pontynen S, Pukander J, Herva E, et al. Efficacy of pneumococcal vaccination against recurrent otitis media. Preliminary results of a field trial in Finland. Ann Otol Rhinol Laryngol Suppl. 1980;89:357–62.PubMedGoogle Scholar
  25. 25.
    Koskela M, Leinonen M, Haiva VM, Timonen M, Makela PH. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis. 1986;5:45–50.PubMedCrossRefGoogle Scholar
  26. 26.
    Leinonen M, Sakkinen A, Kalliokoski R, Luotonen J, Timonen M, Makela PH. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis. 1986;5:39–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol. 1995;7:349–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Balloch A, Licciardi PV, Russell FM, Mulholland EK, Tang ML. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol. 2010;126:395–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Licciardi PV, Balloch A, Russell FM, Burton RL, Lin J, Nahm MH, et al. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. The Journal of allergy & clinical immunology. 2012;129:794–800.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Anne Balloch
    • 1
    Email author
  • Paul V. Licciardi
    • 1
  • Mimi L. K. Tang
    • 1
    • 2
    • 3
  1. 1.Pneumococcal Laboratory, Allergy and Immune DisordersMurdoch Childrens Research InstituteMelbourneAustralia
  2. 2.Department of PaediatricsUniversity of MelbourneMelbourneAustralia
  3. 3.Department of Allergy and ImmunologyRoyal Children’s HospitalMelbourneAustralia

Personalised recommendations